Graduated in Pharmacy-biochemistry at University of São Paulo (2001), PhD in Biotechnology at University of São Paulo (2006), postdoctoral fellow at the Heart Institute, University of São Paulo (2009) and postdoctoral fellow at the Sylvester Cancer Center, University of Miami (2011). He is currently a researcher at the National Laboratory of Biosciences (LNBio / CNPEM / MCTI), coordinating the Immunotherapy Research Group, Viral Vector Core and the Monoclonal Antibodies Engineering Unit. Has experience in immunomodulation, antitumor vaccines, immunomodulatory antibodies, engineering and production of viral vectors for expression or gene silencing, construction of chimeric aptamer RNA. Develops projects in the fields of Biotechnology, virology, gene therapy and cancer immunotherapy. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
In the last decade, there has been a significant development of therapeutic therapies that act on the mechanisms associated to the control of immune tolerance in T cells, mediated by receptors such as CLTA-4 and PD1, also known as immune checkpoints. The use of checkpoint inhibitors revolutionized medical practice. Furthermore, another important lymphocyte immunosuppression mechanism is r…
Immunotherapy approaches have revolutionized perspectives in the treatment of human cancer. Antibodies known as checkpoint inhibitors act on receptors constitutively expressed on lymphocytes, blocking immunosuppressive mechanisms that antagonize the antitumor response. In this way, boosting lymphocyte activity and potentiation of antitumor immune vigilance is stimulated. In recognition of…
The use of new strategies for treatment of cancer, based on immunotherapy have generated surprising results. Most of these strategies are driven to favor the activity of T cells, which are recognized to play an important role in the control and elimination of tumor cells. T cells have surface receptors that transduce signaling mediators of the activation state. The first activation signal…
Here we propose a new platform for antitumor immunotherapy based on the use of nanoparticles. These particles are engineered to interact with specific receptors on target cells in order to drive the tropism. In this proposal we plan to explore new nanoparticle formulations harboring different ligands to evaluate tropism selectivity and immunomodulatory properties. We also propose to gener…
(Only some records are available in English at this moment)
The therapeutic strategies of cancer based on immunotherapy aim to strengthen the activity of cells of the immune system and to inhibit mechanisms of immune tolerance that antagonize the elimination of tumor cells. Regulatory T cells (Treg) protect the body from developing autoimmune diseases, however, in the condition of neoplasia, they can make immunological surveillance difficult and i…
The development of new therapeutic approaches for the treatment of cancer is based on the use of models for evaluation and confirmation of the biological effect. Cell culture assays can provide proofs of concept that warrant testing in more complex biological systems, such as using animal models. In the field of cancer immunotherapy, where the aim is to potentiate cells of the immune syst…
Cancer is a disease in which cells acquire genetic alterations. The tumor may have characteristics that promote its growth, such as the escape of the immune system. This ability to evade the immunity is largely attributed to the existence of immunosuppressive mechanisms that regulate the balance between immunotolerance and immunovigilance, in order to avoid an autoimmune response of T cel…
Clinical samples isolated from patients revealed that the infiltrate of regulatory T cells (Tregs) in the tumor site correlates with the progression of cancer. Data from literature suggests that elimination of Treg cells may act in synergy with other anticancer therapies. Among the most popular strategies, regulatory T cells can be inactivated by depletion, using antibodies or toxins dire…
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing research grants |
| 6 / 4 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 11 / 4 | Completed scholarships in Brazil |
| 20 / 11 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID